The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ER...
The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
About this item
Full title
Author / Creator
Liu, Xuejiao , Chen, Xiangyu , Shi, Lin , Shan, Qianqian , Cao, Qiyu , Yue, Chenglong , Li, Huan , Li, Shengsheng , Wang, Jie , Gao, Shangfeng , Niu, Mingshan and Yu, Rutong
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Glioblastoma (GBM) is a fatal brain tumor, lacking effective treatment. Epidermal growth factor receptor (EGFR) is recognized as an attractive target for GBM treatment. However, GBMs have very poor responses to the first- and second-generation EGFR inhibitors. The third-generation EGFR-targeted drug, AZD9291, is a novel and irreversible inhibitor....
Alternative Titles
Full title
The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_9ff8f18883c842dbaf80e4363393a3e6
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9ff8f18883c842dbaf80e4363393a3e6
Other Identifiers
ISSN
1756-9966,0392-9078
E-ISSN
1756-9966
DOI
10.1186/s13046-019-1235-7
